文献速递消化道肿瘤与早癌消化内镜

真实世界队列中内镜黏膜下剥离术与食管切除术治疗T1期食管鳞状细胞癌的结局比较

Outcomes of Endoscopic Submucosal Dissection vs Esophagectomy for T1 Esophageal Squamous Cell Carcinoma in a Real-World Cohort.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-04-25

中国上海中山医院2011年10月1日至2016年9月31日回顾性队列研究,T1a-m2/m3或T1b食管鳞癌患者接受内镜黏膜下剥离术(ESD,n=322)或食管切除术(n=274)。中位随访21个月,ESD组围手术期非致命严重不良事件比例较低(15.2% vs 27.7%),疾病特异性死亡率较低(3.4% vs 7.4%),全因死亡率(7.4% vs 10.9%)与复发或转移率(9.1% vs 8.9%)无显著差异。

要点

  • ESD组围手术期非致命严重不良事件比例低于食管切除术组(15.2% vs 27.7%,P=.001)。
  • ESD组疾病特异性死亡率低于食管切除术组(3.4% vs 7.4%,P=.049)。
  • 两组全因死亡率(7.4% vs 10.9%,P=.209)与复发或转移率(9.1% vs 8.9%,P=.948)无显著差异。

核心结论

  • 在T1a-m2/m3或T1b食管鳞癌患者中,ESD组围手术期不良事件比例和疾病特异性死亡率低于食管切除术组,但全因死亡率及复发或转移率无显著差异。

研究设计与样本

  • 回顾性队列研究,纳入2011年10月1日至2016年9月31日于中国上海中山医院接受ESD(n=322)或食管切除术(n=274)的T1a-m2/m3或T1b食管鳞癌患者。
  • 主要结局为随访结束时(至少6个月)的全因死亡率;次要结局包括手术时间、住院时间、费用、围手术期死亡或严重非致命不良事件、辅助治疗需求、疾病特异性死亡率及随访结束时的癌症复发或转移。

主要发现

  • ESD组患者年龄较大(平均63.5岁 vs 食管切除术组62.3岁;P=.006),男性比例较高(80.1% vs 70.4%;P=.006),T1a肿瘤比例较高(74.5% vs 27%;P=.001)。
  • ESD组围手术期死亡率较低(0.3% vs 食管切除术组1.5%;P=.186),非致命严重不良事件比例较低(15.2% vs 27.7%;P=.001),其中食管瘘(0.3% vs 16.4%;P=.001)和肺部并发症(0.3% vs 3.6%;P=.004)比例较低。
  • 中位随访21个月(范围6-73个月),两组全因死亡率(ESD组7.4% vs 食管切除术组10.9%;P=.209)及癌症复发或转移率(ESD组9.1% vs 食管切除术组8.9%;P=.948)无显著差异。
  • ESD组疾病特异性死亡率低于食管切除术组(3.4% vs 7.4%;P=.049)。
  • Cox回归分析中,肿瘤浸润深度是唯一与全因死亡率相关的因素(T1a-m3或更深 vs T1a-m2:风险比3.54;P=.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Esophagectomy is the standard treatment for early-stage esophageal squamous cell carcinoma (EESCC), but patients who undergo this procedure have high morbidity and mortality. Endoscopic submucosal dissection (ESD) is a less-invasive procedure for treatment of EESCC, but is considered risky because this tumor frequently metastasizes to the lymph nodes. We aimed to directly compare outcomes of patients with EESCC treated with ESD vs esophagectomy. METHODS: We performed a retrospective cohort study of patients with T1a-m2/m3, or T1b EESCCs who underwent ESD (n = 322) or esophagectomy (n = 274) from October 1, 2011 through September 31, 2016 at Zhongshan Hospital in Shanghai, China. The primary outcome was all-cause mortality at the end of follow up (minimum of 6 months). Secondary outcomes included operation time, hospital stay, cost, perioperative mortalities/severe non-fatal adverse events, requirement for adjuvant therapies, and disease-specific mortality and cancer recurrence or metastasis at the end of the follow up period. RESULTS: Patients who underwent ESD were older (mean 63.5 years vs 62.3 years for patients receiving esophagectomy; P = .006) and a greater proportion was male (80.1% vs 70.4%; P = .006) and had a T1a tumor (74.5% vs 27%; P = .001). A lower proportion of patients who underwent ESD had perioperative mortality (0.3% vs 1.5% of patients receiving esophagectomy; P = .186) and non-fatal severe adverse events (15.2% vs 27.7%; P = .001)-specifically lower proportions of esophageal fistula (0.3% of patients receiving ESD vs 16.4% for patients receiving esophagectomy; P = .001) and pulmonary complications (0.3% vs 3.6%; P = .004). After a median follow-up time of 21 months (range, 6-73 months), there were no significant differences between treatments in all-cause mortality (7.4% for ESD vs 10.9%; P = .209) or rate of cancer recurrence or metastasis (9.1% for ESD vs 8.9%; P = .948). Disease-specific mortality was lower among patients who received ESD (3.4%) vs patients who patients who received esophagectomy (7.4%) (P = .049). In Cox regression analysis, depth of tumor invasion was the only factor associated with all-cause mortality (T1a-m3 or deeper vs T1a-m2: hazard ration, 3.54; P = .04). CONCLUSION: In a retrospective study of patients with T1am2/m3 or T1b EESCCs treated with ESD (n = 322) or esophagectomy (n = 274), we found lower proportions of patients receiving ESD to have perioperative adverse events or disease specific mortality after a median follow up time of 21 months. We found no difference in overall survival or cancer recurrence or metastasis in patients with T1a or T1b ESCCs treated with ESD vs esophagectomy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Ding H, Chen T, et al. Outcomes of Endoscopic Submucosal Dissection vs Esophagectomy for T1 Esophageal Squamous Cell Carcinoma in a Real-World Cohort. Clin Gastroenterol Hepatol. 2018. PMID: 29704682. doi:10.1016/j.cgh.2018.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。